Advisors Asset Management Inc. Has $3.68 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Advisors Asset Management Inc. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,165 shares of the biopharmaceutical company's stock after selling 443 shares during the period. Advisors Asset Management Inc.'s holdings in Regeneron Pharmaceuticals were worth $3,679,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in REGN. Intact Investment Management Inc. bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at $356,000. Principal Financial Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after buying an additional 2,828 shares during the period. Golden State Equity Partners boosted its stake in Regeneron Pharmaceuticals by 1,479.1% during the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock valued at $967,000 after buying an additional 1,272 shares in the last quarter. Fagan Associates Inc. grew its holdings in Regeneron Pharmaceuticals by 42.2% during the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after acquiring an additional 3,832 shares during the period. Finally, ABC Arbitrage SA bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $1,510,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

REGN has been the subject of several research reports. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective for the company. Citigroup reduced their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Sanford C. Bernstein dropped their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research note on Tuesday, February 4th. Finally, Bank of America reaffirmed an "underperform" rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Down 4.1 %

REGN stock traded down $26.86 during trading hours on Tuesday, hitting $634.14. The company's stock had a trading volume of 852,233 shares, compared to its average volume of 635,607. The stock has a 50 day moving average price of $688.31 and a two-hundred day moving average price of $809.71. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The company has a market capitalization of $69.33 billion, a PE ratio of 16.57, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the prior year, the company posted $11.86 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.